Welcome to our dedicated page for Cyduct Diagnostics news (Ticker: CYDX), a resource for investors and traders seeking the latest updates and insights on Cyduct Diagnostics stock.
News about CYduct Diagnostics, Inc. (CYDX) centers on its work as a women’s health-focused medical device and precision medicine company in breast healthcare and wellness. Company announcements highlight research, clinical activities, advocacy efforts, and participation in industry and innovation events related to breast cancer risk assessment and early detection.
Recent releases describe CYduct as a clinical-stage diagnostic company focused on proprietary technologies for the early assessment and detection of breast cancer, including proteomic breast cancer risk assessment tests and biomarker-based diagnostic tools. The company has reported pilot study results on combinations of breast cancer biomarkers using liquid biopsy samples and has announced expanded patient study research on targeted biomarkers for risk assessment and early detection.
Other news items emphasize CYduct’s work with non-invasive intraductal platforms, proteomic technology, and breast health assessment platforms, as well as its participation in conferences and summits where it presents study data on breast cancer detection. The company also issues news about grants and recognition related to its breast cancer risk assessment research, and about sponsorships and support for breast cancer advocacy and research organizations.
Investors, clinicians, and observers following CYDX news can expect updates on breast cancer biomarker studies, proteomic risk assessment initiatives, intraductal and non-invasive diagnostic approaches, corporate presentations at innovation and financing conferences, and the company’s involvement in women’s health advocacy. This news feed brings together these developments to help readers track CYduct’s stated progress in breast health-focused medical devices and diagnostics.
CYduct Diagnostics (OTCPK:CYDX) announced the expansion of its patient study research on targeted breast cancer biomarkers for risk assessment and early detection. The groundbreaking study, supported by the Dr. Susan Love Fund for Breast Cancer Research at Tower Cancer Research Foundation, aims to identify specific biomarker combinations associated with breast cancer development.
Led by Dr. Jill Dietz and Dr. Shari Yosinski, the research utilizes next-generation automated ELISA technology to analyze noninvasively collected patient samples. The study's objective is to detect breast cancer indicators before they become apparent through traditional methods, potentially revolutionizing diagnosis approaches.
According to WHO data cited in the release, nearly 2.5 million women are diagnosed with breast cancer annually. The research aims to improve early detection capabilities, which could significantly enhance treatment outcomes and reduce the need for aggressive therapies.
CYduct Diagnostics (OTC Pink: CYDX), a clinical-stage diagnostic company specializing in early breast cancer detection technologies, has announced its participation in The Reg A & Crowdfunding Conference. The event is scheduled for June 20, 2024, at the Westchester Country Club in Rye, New York. Dom Gatto, the President and CEO, will be available for meetings during the conference. Attendees can connect with him through the conference app. For registration details, please follow the provided link.
CYduct Diagnostics will present at the 2024 Yale Innovation Summit on May 29-30 in New Haven, CT. The company, specializing in non-invasive intraductal breast health technology, will showcase study data on its proteomic technology, which aims to enhance breast cancer detection and patient care. The Summit, celebrating its 10th year, is a major event in the innovation sector, featuring industry leaders from various fields. CYduct's CEO, Dom Gatto, highlighted the benefits of molecular innovations, emphasizing the company's role in improving diagnostic accuracy, reducing unnecessary surgeries, and enhancing early detection and treatment of breast cancer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.